141 related articles for article (PubMed ID: 36943767)
1. Prognostic factors of childhood acute lymphoblastic leukemia with TCF3::PBX1 in CCCG-ALL-2015: A multicenter study.
Zhang H; Wan Y; Wang H; Cai J; Yu J; Hu S; Fang Y; Gao J; Jiang H; Yang M; Liang C; Jin R; Tian X; Ju X; Hu Q; Jiang H; Li Z; Wang N; Sun L; Leung AWK; Wu X; Qian X; Qian M; Li CK; Yang J; Tang J; Zhu X; Shen S; Zhang L; Pui CH; Zhai X
Cancer; 2023 Jun; 129(11):1691-1703. PubMed ID: 36943767
[TBL] [Abstract][Full Text] [Related]
2. Long-Term Results of the Risk-Stratified Treatment of TCF3-PBX1-Positive Pediatric Acute Lymphoblastic Leukemia in China.
Wang Y; Xue YJ; Lu AD; Jia YP; Zuo YX; Zhang LP
Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):e137-e144. PubMed ID: 33221150
[TBL] [Abstract][Full Text] [Related]
3. [Report of Chinese Children's Cancer Group acute lymphoblastic leukemia 2015 multicenter study].
Chinese Children′s Cancer Group Acute Lymphoblastic Leukemia 2015 Study Group
Zhonghua Er Ke Za Zhi; 2022 Oct; 60(10):1002-1010. PubMed ID: 36207846
[No Abstract] [Full Text] [Related]
4. [Clinical Significance of Minimal Residual Disease in Pediatric Patients with
Xue YJ; Lu AD; Wang Y; Jia YP; Zuo YX; Zhang LP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Oct; 31(5):1303-1308. PubMed ID: 37846676
[TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of t(1;19)/ TCF3-PBX1 in childhood acute lymphoblastic leukemia in the context of Berlin-Frankfurt-Münster-based protocols.
Felice MS; Gallego MS; Alonso CN; Alfaro EM; Guitter MR; Bernasconi AR; Rubio PL; Zubizarreta PA; Rossi JG
Leuk Lymphoma; 2011 Jul; 52(7):1215-21. PubMed ID: 21534874
[TBL] [Abstract][Full Text] [Related]
6. The clinical outcomes and genomic landscapes of acute lymphoblastic leukemia patients with E2A-PBX1: A 10-year retrospective study.
Zhou B; Chu X; Tian H; Liu T; Liu H; Gao W; Chen S; Hu S; Wu D; Xu Y
Am J Hematol; 2021 Nov; 96(11):1461-1471. PubMed ID: 34406703
[TBL] [Abstract][Full Text] [Related]
7. Clinical features and prognostic significance of TCF3-PBX1 fusion gene in Chinese children with acute lymphoblastic leukemia by using a modified ALL-BFM-95 protocol.
Pang L; Liang Y; Pan J; Wang JR; Chai YH; Zhao WL
Pediatr Hematol Oncol; 2015 Apr; 32(3):173-81. PubMed ID: 25551271
[TBL] [Abstract][Full Text] [Related]
8. [Clinical Features and Prognosis of Acute T-cell Lymphoblastic Leukemia in Children--Multi-Center Data Analysis in Fujian].
Wu CP; Zheng YZ; Li J; Wen H; Weng KZ; Zhuang SQ; Wu XG; Hua XL; Zheng H; Chen ZS; LE SH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):6-13. PubMed ID: 38387892
[TBL] [Abstract][Full Text] [Related]
9. [Prognostic significance and risk factors of minimal residual disease ≥1% on 19th day of induction chemotherapy in children with acute lymphoblastic leukemia].
Yu J; Yi T; Lin G; Wen J; Chen L; Chen J; Wu X
Nan Fang Yi Ke Da Xue Xue Bao; 2020 Feb; 40(2):255-261. PubMed ID: 32376526
[TBL] [Abstract][Full Text] [Related]
10. Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia.
Spinelli O; Peruta B; Tosi M; Guerini V; Salvi A; Zanotti MC; Oldani E; Grassi A; Intermesoli T; Micò C; Rossi G; Fabris P; Lambertenghi-Deliliers G; Angelucci E; Barbui T; Bassan R; Rambaldi A
Haematologica; 2007 May; 92(5):612-8. PubMed ID: 17488684
[TBL] [Abstract][Full Text] [Related]
11. [Long-term results of multicenter study based on childhood acute lymphoblastic leukemia 2005 protocol].
Cai JY; Wang NL; Jiang H; Shen SH; Xue HL; Chen J; Pan C; Gao YJ; Sun LR; Yuan XJ; Gu LJ; Tang JY
Zhonghua Er Ke Za Zhi; 2018 Jul; 56(7):511-517. PubMed ID: 29996184
[No Abstract] [Full Text] [Related]
12. Incidence and outcome of TCF3-PBX1-positive acute lymphoblastic leukemia in Austrian children.
Kager L; Lion T; Attarbaschi A; Koenig M; Strehl S; Haas OA; Dworzak MN; Schrappe M; Gadner H; Mann G;
Haematologica; 2007 Nov; 92(11):1561-4. PubMed ID: 18024406
[TBL] [Abstract][Full Text] [Related]
13. Treating childhood acute lymphoblastic leukemia without cranial irradiation.
Pui CH; Campana D; Pei D; Bowman WP; Sandlund JT; Kaste SC; Ribeiro RC; Rubnitz JE; Raimondi SC; Onciu M; Coustan-Smith E; Kun LE; Jeha S; Cheng C; Howard SC; Simmons V; Bayles A; Metzger ML; Boyett JM; Leung W; Handgretinger R; Downing JR; Evans WE; Relling MV
N Engl J Med; 2009 Jun; 360(26):2730-41. PubMed ID: 19553647
[TBL] [Abstract][Full Text] [Related]
14. Extended vincristine and dexamethasone pulse therapy may not be necessary for children with TCF3-PBX1 positive acute lymphoblastic leukaemia.
Wan Y; Zhang H; Zhang L; Cai J; Yu J; Hu S; Fang Y; Gao J; Jiang H; Yang M; Liang C; Jin R; Tian X; Ju X; Hu Q; Jiang H; Li H; Wang N; Sun L; Leung AWK; Wu X; Wang J; Li CK; Yang J; Tang J; Shen S; Zhai X; Pui CH; Zhu X
Br J Haematol; 2022 Nov; 199(4):587-596. PubMed ID: 36114009
[TBL] [Abstract][Full Text] [Related]
15. Prognostic heterogeneity of adult B-cell precursor acute lymphoblastic leukaemia patients with t(1;19)(q23;p13)/TCF3-PBX1 treated with measurable residual disease-oriented protocols.
Ribera J; Granada I; Morgades M; González T; Ciudad J; Such E; Calasanz MJ; Mercadal S; Coll R; González-Campos J; Tormo M; García-Cadenas I; Gil C; Cervera M; Barba P; Costa D; Ayala R; Bermúdez A; Orfao A; Ribera JM;
Br J Haematol; 2022 Feb; 196(3):670-675. PubMed ID: 34549416
[TBL] [Abstract][Full Text] [Related]
16. [Treatment outcome of childhood standard-risk and median-risk acute lymphoblastic leukemia with CCLG-2008 protocol].
Liu X; Zou Y; Wang H; Chen X; Ruan M; Chen Y; Yang W; Guo Y; Liu T; Zhang L; Wang S; Zhang J; Liu F; Cai X; Qi B; Chang L; Zhu X
Zhonghua Er Ke Za Zhi; 2014 Jun; 52(6):449-54. PubMed ID: 25190166
[TBL] [Abstract][Full Text] [Related]
17. Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study.
Pui CH; Pei D; Coustan-Smith E; Jeha S; Cheng C; Bowman WP; Sandlund JT; Ribeiro RC; Rubnitz JE; Inaba H; Bhojwani D; Gruber TA; Leung WH; Downing JR; Evans WE; Relling MV; Campana D
Lancet Oncol; 2015 Apr; 16(4):465-74. PubMed ID: 25800893
[TBL] [Abstract][Full Text] [Related]
18. Clinical features and prognostic impact of TCF3-PBX1 in childhood acute lymphoblastic leukemia: A single-center retrospective study of 837 patients from China.
Jia M; Hu BF; Xu XJ; Zhang JY; Li SS; Tang YM
Curr Probl Cancer; 2021 Dec; 45(6):100758. PubMed ID: 34034913
[TBL] [Abstract][Full Text] [Related]
19. Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial.
Vora A; Goulden N; Mitchell C; Hancock J; Hough R; Rowntree C; Moorman AV; Wade R
Lancet Oncol; 2014 Jul; 15(8):809-18. PubMed ID: 24924991
[TBL] [Abstract][Full Text] [Related]
20. Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT.
Pavlů J; Labopin M; Niittyvuopio R; Socié G; Yakoub-Agha I; Wu D; Remenyi P; Passweg J; Beelen DW; Aljurf M; Kröger N; Labussière-Wallet H; Perić Z; Giebel S; Nagler A; Mohty M
J Hematol Oncol; 2019 Oct; 12(1):108. PubMed ID: 31647022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
